Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. (SION) priced its initial public offering on Feb 7, 2025 at $18.00 per share, raising $190.6M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $765.4M. Goodwin Procter advised the company and Ropes & Gray advised the underwriters.

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for cystic fibrosis. Its small molecules aim to stabilize the nucleotide-binding domain 1 of the CFTR protein to correct defects caused by the F508del mutation.

Status

IPO

Ticker

SION

Exchange

Nasdaq Global Market

Priced

Feb 7, 2025

IPO price

$18.00

Raised

$190.6M

Market cap at IPO price

$765.4M

First filed

Jan 17, 2025

Company counsel

Goodwin Procter

Underwriters' counsel

Ropes & Gray

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.